JP2022500419A5 - - Google Patents

Info

Publication number
JP2022500419A5
JP2022500419A5 JP2021513959A JP2021513959A JP2022500419A5 JP 2022500419 A5 JP2022500419 A5 JP 2022500419A5 JP 2021513959 A JP2021513959 A JP 2021513959A JP 2021513959 A JP2021513959 A JP 2021513959A JP 2022500419 A5 JP2022500419 A5 JP 2022500419A5
Authority
JP
Japan
Prior art keywords
domain
cytotoxic
receptor
population
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500419A (ja
JP7520818B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050679 external-priority patent/WO2020056045A1/en
Publication of JP2022500419A publication Critical patent/JP2022500419A/ja
Publication of JP2022500419A5 publication Critical patent/JP2022500419A5/ja
Priority to JP2024110682A priority Critical patent/JP2024149496A/ja
Application granted granted Critical
Publication of JP7520818B2 publication Critical patent/JP7520818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513959A 2018-09-13 2019-09-11 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 Active JP7520818B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024110682A JP2024149496A (ja) 2018-09-13 2024-07-10 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862730939P 2018-09-13 2018-09-13
US62/730,939 2018-09-13
US201962821360P 2019-03-20 2019-03-20
US62/821,360 2019-03-20
US201962841768P 2019-05-01 2019-05-01
US62/841,768 2019-05-01
US201962875893P 2019-07-18 2019-07-18
US62/875,893 2019-07-18
PCT/US2019/050679 WO2020056045A1 (en) 2018-09-13 2019-09-11 Natural killer cell compositions and immunotherapy methods for treating tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024110682A Division JP2024149496A (ja) 2018-09-13 2024-07-10 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法

Publications (3)

Publication Number Publication Date
JP2022500419A JP2022500419A (ja) 2022-01-04
JP2022500419A5 true JP2022500419A5 (cg-RX-API-DMAC7.html) 2022-09-20
JP7520818B2 JP7520818B2 (ja) 2024-07-23

Family

ID=69778429

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513959A Active JP7520818B2 (ja) 2018-09-13 2019-09-11 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法
JP2024110682A Pending JP2024149496A (ja) 2018-09-13 2024-07-10 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024110682A Pending JP2024149496A (ja) 2018-09-13 2024-07-10 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法

Country Status (8)

Country Link
US (2) US20210338727A1 (cg-RX-API-DMAC7.html)
EP (1) EP3850004B1 (cg-RX-API-DMAC7.html)
JP (2) JP7520818B2 (cg-RX-API-DMAC7.html)
CN (1) CN113166225A (cg-RX-API-DMAC7.html)
AU (1) AU2019337603B2 (cg-RX-API-DMAC7.html)
CA (1) CA3112195A1 (cg-RX-API-DMAC7.html)
ES (1) ES3068417T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020056045A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
CN111423517B (zh) * 2020-04-15 2023-05-12 赛德特生物制药有限公司 一种肿瘤细胞干性限制型car及其应用
MX2022015586A (es) 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
WO2022215843A1 (ko) * 2021-04-06 2022-10-13 (주)에스엠티바이오 암 환자에 대하여 자연살해세포를 이용한 면역 항암 치료의 치료 반응성을 예측하는 방법
CA3218640A1 (en) * 2021-05-13 2022-11-17 Kanya Lakshmi RAJANGAM Dosing regimens for cancer immunotherapy
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
CN118215683A (zh) * 2021-11-09 2024-06-18 悟境股份有限公司 记忆nk细胞和抗癌双特异性分子的组合癌症疗法
TW202405165A (zh) * 2022-04-14 2024-02-01 日商第一三共股份有限公司 編碼膜型細胞激素及tnf受體超家族分子之細胞內域的多核苷酸
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024080726A1 (ko) * 2022-10-13 2024-04-18 (주) 테라베스트 자연살해세포 및 토포이소머라제 저해제를 유효성분으로 포함하는 암 예방 및 치료용 약학 조성물
CN120092090A (zh) * 2022-11-07 2025-06-03 上海先博生物科技有限公司 工程化嵌合抗原受体免疫细胞及其应用
JP2025538424A (ja) * 2022-11-16 2025-11-28 ンカルタ・インコーポレイテッド 併用療法の投与レジメン
WO2024254774A1 (zh) * 2023-06-14 2024-12-19 香港北恒生物科技有限公司 免疫细胞联合疗法
EP4735011A1 (en) * 2023-06-27 2026-05-06 Nkarta, Inc. Dosing regimens for treatment of cancer
CN118440901B (zh) * 2024-04-26 2025-03-07 康立泰生物医药(青岛)有限公司 转基因nk细胞及其构建方法和应用
CN118406654B (zh) * 2024-04-26 2025-03-21 中国海洋大学 经修饰的nk细胞及其构建方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123276D0 (en) * 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2005076843A2 (en) * 2004-02-06 2005-08-25 Elan Pharmaceuticals, Inc. Methods and compositions for treating tumors and metastatic disease
WO2014040143A1 (en) * 2012-09-17 2014-03-20 Gray Bruce N Method of treating cancer
SG11201505858VA (en) * 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
WO2014140884A2 (en) * 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands
CN107074957B (zh) * 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
WO2015150097A1 (en) * 2014-04-04 2015-10-08 Iomet Pharma Ltd Indole derivatives for use in medicine
US9801627B2 (en) * 2014-09-26 2017-10-31 Ethicon Llc Fastener cartridge for creating a flexible staple line
EP3805371A1 (en) * 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
EP3712171A1 (en) * 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
US10577417B2 (en) * 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3240908A2 (en) * 2014-12-30 2017-11-08 F. Hoffmann-La Roche AG Methods and compositions for prognosis and treatment of cancers
US10471098B2 (en) * 2015-04-15 2019-11-12 Prospect Chartercare Rwmc, Llc Hepatic arterial infusion of CAR-T cells
US12241053B2 (en) * 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
US10875919B2 (en) * 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
TW201825511A (zh) * 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
EP3532091A2 (en) * 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
WO2018124766A2 (ko) * 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
CN110913954A (zh) * 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
CN117363636A (zh) * 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸

Similar Documents

Publication Publication Date Title
Alnefaie et al. Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions
Hodgins et al. Killers 2.0: NK cell therapies at the forefront of cancer control
Dai et al. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
Al-Haideri et al. CAR-T cell combination therapy: the next revolution in cancer treatment
Harris et al. Immuno-oncology combinations: raising the tail of the survival curve
Dempke et al. Second-and third-generation drugs for immuno-oncology treatment—the more the better?
CN110475571B (zh) 细胞免疫疗法前细胞毒性预调理的替代
TWI786044B (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
JP6787792B2 (ja) がんの処置のための併用治療
Huang et al. Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma
US20240066040A1 (en) Ep4 inhibitors and use thereof
Duru et al. A window of opportunity: targeting cancer endothelium to enhance immunotherapy
Dolkar et al. New developments in immunotherapy for SCLC
KR20150080507A (ko) 면역 반응의 향상
JP2022189827A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
Huang et al. Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses
JP2021502416A5 (cg-RX-API-DMAC7.html)
Su et al. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Morganti et al. Combinations using checkpoint blockade to overcome resistance
Demel et al. Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021
WO2022052874A1 (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
Kim et al. Calcipotriol, a synthetic Vitamin D analog, promotes antitumor immunity via CD4+ T-dependent CTL/NK cell activation
Li et al. Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments
JP2024513506A (ja) がんの治療のためのCD47/SIRPα結合及びNEDD8活性化酵素E1調節サブユニットの共阻害
Swan et al. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies